Open Book Extracts appoints two strategic advisors

Dr Emmanuelle Schuler will serve on the company's scientific advisory bord, while Dr John Weatherspoon will advise the company on intellectual property decisions

Open Book Extracts (OBX), manufacturer and distributor of cannabinoid ingredients, has appointed two strategic corporate advisors. Dr Emmanuelle Schuler serves as founding member of the OBX scientific advisory board and Dr John Weatherspoon will serve as intellectual property advisor.

Dr Emmanuelle Schuler, OBX Scientific Advisor

Dr Schuler previously served as the head of JLABS@TMC, Johnson & Johnson's life science incubator, collaborating with internal groups to attract companies in alignment with their strategic efforts. Prior to joining J&J, Dr Schuler led IP-based transactions at MD Anderson Cancer Center and previously was responsible for industry-based strategic collaborations at the University of Houston.

Dr Weatherspoon is a registered U.S. patent attorney, having served as a patent attorney at Morgan Lewis and Winston Strawn. He is co-founder of Affirmed Pharma, an Advisor at Mili Pharmaceuticals, and regularly advises on patent strategy and building patent portfolios for clients.

“As with our previously appointed advisors, each appointee joining OBX comes from sectors outside the cannabis category and is a testament to the broad appeal of the industry and the unique opportunity to make an impact through OBX,” said Dave Neundorfer co-founder and CEO of BX.

Dr John Weatherspoon, OBX IP Advisor

OBX has recently embarked on several of its own research-backed product development initiatives, targeting the nutraceutical, skincare, and veterinary markets. The company aims to commercialise its findings through licensing deals or joint venture partnerships with consumer brands.

All the recent corporate advisor appointments follow the company’s announcement of a reciprocal research collaboration with Case Western Reserve University School of Medicine (CWRU) to explore the mechanistic effects of cannabinoids on brain cell function.

Companies